Trump’s ACA Repeal: What’s In It For Biopharma?

09 Nov 2016

Trump’s drive to repeal the Affordable Care Act offers opportunities for biopharma to eliminate the annual drug tax and roll back programs that could enable implementation of US government price controls on drugs without congressional action.

President-elect Donald Trump’s campaign pledge to repeal and replace the Affordable Care Act could open the door to eliminating the ACA’s annual tax on branded drugs and to blocking two programs that are empowered by the law to implement drug price controls without the need for congressional action.

That opportunity is a positive for biopharma despite the prospect that millions of people may lose access to insurance, and...